Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Politics

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by admin October 3, 2025
October 3, 2025
Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

previous post
Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin
next post
Reagan-appointed judge, once rebuked by Supreme Court, continues to lambaste Trump

related articles

Hegseth orders Pentagon to launch comprehensive review into...

May 21, 2025

Iran talks with Europeans set for Friday; White...

June 20, 2025

Vulnerable Democrats hammered with scathing ad handcuffing them...

August 14, 2025

RFK Jr. wants to disrupt our powerful health...

November 19, 2024

Trump cabinet picks delight Taiwan, send strong signal...

November 13, 2024

Trump watches strike on Iran-backed Houthis in Yemen...

March 16, 2025

White House drops ‘Daddy’s Home’ meme after viral...

June 27, 2025

DAVID MARCUS: Drone debacle perfect end to Biden’s...

December 16, 2024

Trump guest shares special message to president after...

March 6, 2025

EXCLUSIVE: White House rolls out implementation of AI...

April 10, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 2

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 3

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024
    • 4

      Lode Gold Launches Exploration Program at One of the Largest Land Packages in New Brunswick

      October 19, 2024
    • 5

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024

    Categories

    • Investing (2,599)
    • Latest News (2,300)
    • Politics (3,132)
    • Stocks (990)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved